KDR and Thrombocytopenia: Although the development of TKIs targeting VEGFR2 opens a new door for advanced RCC patients, the huge costs and side effects, such as neutropenia, anemia, increased creatinine, thrombocytopenia and hand-foot syndrome may become the stumbling block of these treatments32.